MedTrace Logo

A Study of V950 in People With Alzheimer Disease (V950-001 AM7)

NCT00464334 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2015-09-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety, tolerability and the immune response to an investigational vaccine, V950, with or without ISCOMATRIX™ (IMX).

Conditions

  • Alzheimer Disease

Interventions

BIOLOGICAL

V950

V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

BIOLOGICAL

ISCOMATRIX™

ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

BIOLOGICAL

Placebo to V950

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2012-01-31
Completion
2012-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00464334 on ClinicalTrials.gov